Who is eligible for clinical trial NCT05356117?

Participants must meet protocol criteria for Pancreatic Cancer. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05356117 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-17

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial (NCT05356117)

🟢 Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Dana-Farber Cancer Institute

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this research is to determine whether a virtually supervised resistance exercise (RE) intervention combined with protein supplementation (PS) is feasible in pancreatic cancer patients initiating chemotherapy and if it will improve skeletal muscle mass. The names of the study interventions involved in this study are: * Resistance training and protein supplement intake (RE + PS) * Resistance training (RE) * Attention control (AC), home-based stretching

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (12 items).

Location: Dana Farber Cancer Institute — Boston, Massachusetts

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Non-metastatic pancreatic cancer patients initiating neoadjuvant chemotherapy.
Ability to understand and the willingness to sign a written informed consent document.
Over the age of 18 years; children under the age of 18 will be excluded due to rarity of disease.
Speak English or Spanish.
Able to provide physician clearance to participate in the exercise program.
Able to initiate a supervised exercise program (free from any cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity).
Currently participate in less than or equal to 60 minutes of structured moderate or vigorous exercise/week.
Does not smoke (no smoking during previous 12 months).
Willing to travel to DFCI for assessments.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patients should not have any uncontrolled illness including ongoing or active infection, uncontrolled diabetes, hypertension or thyroid disease.
Patients may not be receiving any other investigational agents.
Patients with other active malignancies are ineligible for this study.
Patients with metastatic disease.
History of any musculoskeletal, cardiorespiratory or neurological diseases that preclude the participation in exercise.
Patients expected to receive other cancer directed treatments during the study and assessment period.
Participates in more than 60 minutes of structured moderate or vigorous exercise/week.
Currently smokes.
Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Is unable to travel to DFCI for assessments.
Patients who are pregnant due to the unknown effects of exercise on the developing fetus.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Dana Farber Cancer Institute — Boston, Massachusetts

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗